Secukinumab, as an anti-interleukin-17A monoclonal antibody, usually used for treatment with the ankylosing spondylitis[1].
In vitro experiment it indicated that when IL-17A at 956.2 ng/mL, secukinumab was obviously less potent[2].
In vivo clinical trail it suggested that treatment with 150 mg secukinumab subcutaneously or intravenously in patients remarkedly reduced the signs and symptoms of ankylosing spondylitis at week 16. While treatment with 75 mg secukinumab subcutaneously caused obvious improvement only with a higher intravenous loading dose.[1] Secukinumab has a highly favorable safety profile. In clinical test it demonstrated that treatment with 300 mg secukinumab, for occurs at a rate of 3.55/100 subject-years of mucocutaneous candidiasis, these infections usually do not interfere with maintenance of secukinumab therapy. Thus, secukinumab has an effictive new treatment for individuals with moderate-to-severe psoriasis.[3] In pivotal phase III trials, at dose of 75–150 mg and 75–300 mg secukinumab subcutaneously in pediatric patients aged 6 to < 18 years, there is an markedly improvemnet compared with placebo. It is suggested that secukinumab improved health-related quality of life and was generally well tolerated. [4] In efficacy trail it indicated that in received subcutaneous secukinumab 150?mg with (LD) or without (NL) loading dose patients or placebo weekly, secukinumab significantly improved the signs and symptoms of nr-axSpA across patients grouped by C-reactive protein (+/?) and/or magnetic resonance imaging (+/?) status, HLA-B27 (+/?) status, and sex[5].
References:
[1]Baeten D, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534-48.
[2]Adams R, et al. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F. Front Immunol. 2020 Aug 21;11:1894.
[3]Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016 Oct;15(10):1413-20.
[4]Blair HA. Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis. Paediatr Drugs. 2021 Nov;23(6):601-608.
[5]Braun J, et al. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Res Ther. 2021 Sep 4;23(1):231.
苏金单抗作为一种抗白细胞介素17A的单克隆抗体,通常用于治疗强直性脊柱炎[1]。
体外实验表明,当IL-17A浓度为956.2 ng/mL时,苏金单抗的作用明显减弱[2]。
体内临床试验表明,在第 16 周时,皮下或静脉注射 150 mg 苏金单抗可显着减轻强直性脊柱炎的症状和体征。而皮下注射 75 mg 苏金单抗仅在较高的静脉负荷剂量下才会有明显改善.[1] 苏金单抗具有高度有利的安全性。在临床试验中,它证明用 300 mg 苏金单抗治疗,以 3.55/100 受试者年的比率发生皮肤粘膜念珠菌病,这些感染通常不会干扰苏金单抗治疗的维持。因此,苏金单抗对于中度至重度银屑病患者来说是一种有效的新疗法。[3]在关键的 III 期试验中,苏金单抗皮下注射 75-150 mg 和 75-300 mg 苏金单抗用于儿科6 岁至 < 的患者； 18年,与安慰剂相比有明显改善。这表明苏金单抗改善了与健康相关的生活质量,并且总体上耐受性良好。 [4] 在疗效试验中,它表明在每周接受皮下注射苏金单抗 150mg 负荷剂量 (LD) 或不负荷剂量 (NL) 或安慰剂的患者中,苏金单抗显着改善了 nr-axSpA 的体征和症状按 C 反应蛋白 (+/-) 和/或磁共振成像 (+/-) 状态、HLA-B27 (+/-) 状态和性别分组的患者[5]。